JP2019504103A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504103A5
JP2019504103A5 JP2018540797A JP2018540797A JP2019504103A5 JP 2019504103 A5 JP2019504103 A5 JP 2019504103A5 JP 2018540797 A JP2018540797 A JP 2018540797A JP 2018540797 A JP2018540797 A JP 2018540797A JP 2019504103 A5 JP2019504103 A5 JP 2019504103A5
Authority
JP
Japan
Prior art keywords
formula
crystalline form
compound
crystalline
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504103A (ja
JP6877450B2 (ja
Filing date
Publication date
Priority claimed from CN201610081899.3A external-priority patent/CN107043377A/zh
Application filed filed Critical
Publication of JP2019504103A publication Critical patent/JP2019504103A/ja
Publication of JP2019504103A5 publication Critical patent/JP2019504103A5/ja
Application granted granted Critical
Publication of JP6877450B2 publication Critical patent/JP6877450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540797A 2016-02-05 2017-02-04 Tlr7アゴニストのトリフルオロ酢酸塩及びその結晶形b、調製方法、並びに使用 Active JP6877450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610081899.3 2016-02-05
CN201610081899.3A CN107043377A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
PCT/CN2017/072894 WO2017133687A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途

Publications (3)

Publication Number Publication Date
JP2019504103A JP2019504103A (ja) 2019-02-14
JP2019504103A5 true JP2019504103A5 (enExample) 2020-02-27
JP6877450B2 JP6877450B2 (ja) 2021-05-26

Family

ID=59500539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540797A Active JP6877450B2 (ja) 2016-02-05 2017-02-04 Tlr7アゴニストのトリフルオロ酢酸塩及びその結晶形b、調製方法、並びに使用

Country Status (23)

Country Link
US (1) US10683296B2 (enExample)
EP (1) EP3412674B1 (enExample)
JP (1) JP6877450B2 (enExample)
KR (1) KR102393281B1 (enExample)
CN (2) CN107043377A (enExample)
AR (1) AR107550A1 (enExample)
AU (1) AU2017214135B2 (enExample)
CA (1) CA3013521C (enExample)
CL (1) CL2018002101A1 (enExample)
DK (1) DK3412674T3 (enExample)
EA (1) EA037048B1 (enExample)
ES (1) ES2834304T3 (enExample)
HU (1) HUE052210T2 (enExample)
IL (1) IL260981B (enExample)
MX (1) MX374300B (enExample)
MY (1) MY198137A (enExample)
NZ (1) NZ745023A (enExample)
PH (1) PH12018501641B1 (enExample)
SG (1) SG11201806688QA (enExample)
TW (1) TWI778952B (enExample)
UA (1) UA121276C2 (enExample)
WO (1) WO2017133687A1 (enExample)
ZA (1) ZA201805240B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913587WA (en) 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN112105620B (zh) * 2018-05-25 2026-02-24 正大天晴药业集团股份有限公司 用于治疗肺癌的tlr7激动剂及其药物组合
BR112021015577A8 (pt) 2019-02-08 2021-10-05 Research & Business Found Sungkyunkwan Univ Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo
EP4115901A4 (en) 2020-03-02 2024-04-10 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
EP4194010A4 (en) 2020-08-04 2025-03-26 Progeneer Inc. Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof
WO2023137035A1 (en) 2022-01-12 2023-07-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
US9139590B2 (en) 2011-02-04 2015-09-22 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2013103967A1 (en) 2012-01-05 2013-07-11 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
EA035327B1 (ru) * 2012-10-10 2020-05-28 Янссен Сайенсиз Айрлэнд Юси Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
CA2890201A1 (en) * 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
SG11201608299TA (en) * 2014-05-01 2016-11-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
KR102139847B1 (ko) * 2014-05-01 2020-07-31 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
CN105367576A (zh) 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
MX386981B (es) 2014-08-15 2025-03-19 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Similar Documents

Publication Publication Date Title
JP2019505533A5 (enExample)
JP2019505532A5 (enExample)
JP2021530565A5 (enExample)
JP2014501282A5 (enExample)
JP2013049690A5 (enExample)
JP6483674B2 (ja) 5−ブロモ−2−(α−ヒドロキシペンチル)安息香酸ナトリウム塩の複数の異なる結晶型及びそれらの調製方法
JP2017505329A5 (enExample)
RU2018145948A (ru) Кристалл пирролопиримидина для получения jak-ингибитора
JP2015522644A5 (enExample)
JP2016510323A5 (enExample)
JP2013516473A5 (enExample)
HRP20201644T1 (hr) Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba
JP2009537603A (ja) 5−アミノ−3−(2’,3’−ジ−O−アセチル−ベータ−D−リボフラノシル)−3H−チアゾロ[4,5−d]ピリミジン−2−オンのマレイン酸塩のA型及びB型結晶形
JP2020517611A5 (enExample)
JP2017506666A5 (enExample)
JP2011512396A (ja) 新規な多形およびその調製方法
JP2009542787A5 (enExample)
CN102766139B (zh) 阿齐沙坦的多晶型物及其制备方法
JP2019527724A5 (enExample)
JP2024521412A5 (enExample)
JP2016510768A5 (enExample)
JP2022060192A5 (enExample)
JP2018522945A5 (enExample)
TWI808069B (zh) [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式
CN107698574B (zh) 一种高纯度阿瑞匹坦的精制制备工艺